DUBLIN--(BUSINESS WIRE)--The "Women Infertility - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Women Infertility - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 7, 16, 14, 1, 22, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 3 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Women Infertility - Overview
- Women Infertility - Therapeutics Development
- Women Infertility - Therapeutics Assessment
- Women Infertility - Companies Involved in Therapeutics Development
- Women Infertility - Drug Profiles
- Women Infertility - Dormant Projects
- Women Infertility - Discontinued Products
- Women Infertility - Product Development Milestones
- Appendix
- 4P Therapeutics LLC
- AbbVie Inc
- Addex Therapeutics Ltd
- APAvadis Biotechnologies Srl
- ASKA Pharmaceutical Co Ltd
- Astellas Pharma Inc
- Bayer AG
- Cadila Healthcare Ltd
- Dong-A Socio Holdings Co Ltd
- ElexoPharm GmbH
- EndoCeutics Inc
- Enteris BioPharma Inc
- Evotec AG
- Ferring International Center SA
- Forendo Pharma Ltd
- Glycotope GmbH
- Isifer AB
- Kissei Pharmaceutical Co Ltd
- Lipicard Technologies Ltd
- Livzon Pharmaceutical Group Inc
- Luye Pharma Group Ltd
- Myovant Sciences Ltd
- Navya Biologicals Pvt Ltd
- Nippon Shinyaku Co Ltd
- Nora Therapeutics Inc
- ObsEva SA
- Ogeda SA
- Pantec Biosolutions AG
- Philogen SpA
- Repros Therapeutics Inc
- Richter Gedeon Nyrt
- SK Chemicals Co Ltd
- Takeda Pharmaceutical Co Ltd
- ValiRx Plc
- Viramal Ltd
For more information about this report visit https://www.researchandmarkets.com/research/d6fzdf/women_infertility?w=4
